Topical Eflornithine for Pseudofolliculitis Barbae: RCT
Status:
Not yet recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
To study the efficacy of topical eflornithine for pseudofolliculitis barbae from a quality of
life standpoint and with objective physician-measured lesion counts. Our hypothesis is that
the hair growth retardation that occurs with eflornithine will perhaps reduce the frequency
over time that service members need to shave which could improve the formation of PFB
lesions.